Company profile: Credence MedSystems
1.1 - Company Overview
Company description
- Provider of drug delivery and specialty pharmaceutical solutions focused on safe medication administration, offering syringe systems including the Companion Safety Syringe with end-of-dose cues, passive needlestick safety, reuse prevention and pre-attached needle; Dual Chamber Reconstitution Syringe; Credence Connect for real-time injection monitoring; Micro-Dose Syringe for ocular use; and Multi-Site Syringe.
Products and services
- Credence Connect: Enables real-time injection monitoring and feedback, captures dose history, and facilitates proper use through multiple user cues
- Companion Safety Syringe System: Delivers end-of-dose cues, passive needlestick safety, and reuse prevention with a pre-attached needle for simplified use
- Dual Chamber Reconstitution Syringe: Supplies single-step reconstitution and injection with passive needlestick safety, offering an alternative to ready-to-inject products
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Credence MedSystems
Qnovia
HQ: United States
Website
- Description: Provider of medtech and pharmaceutical drug-delivery solutions, including RespiRx, an inhalable prescription nicotine replacement therapy for smoking cessation; an inhaled drug delivery platform that optimizes and tracks dosing to improve efficacy and compliance; and a portable, orientation-agnostic vibrating mesh nebulizer with a digital metered dose interface, Bluetooth-enabled app, and a zero-maintenance disposable cartridge.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qnovia company profile →
Nutriband
HQ: United States
Website
- Description: Provider of abuse-deterrent transdermal technologies and drug delivery systems, including the AVERSA platform integrating abuse-deterrent features into patches for fentanyl, buprenorphine, and methylphenidate, and 4P transdermal systems delivering Exenatide for Type 2 Diabetes and FSH for infertility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nutriband company profile →
Aquarius Bio
HQ: United States
Website
- Description: Provider of a proprietary drug delivery platform to improve existing drugs, specializing in biotechnology, medicine, and pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aquarius Bio company profile →
Cellectar Biosciences
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer therapies and diagnostics, designing phospholipid drug conjugates that target tumor cells to detect, treat, and monitor cancers. Lead candidate iopofosine I 131 is in Phase 2/1 studies. Pipeline includes CLR 1900 cytotoxic compounds and collaborative PDC programs (CLR 2000, CLR 12120) with Avicenna and Orano Med, plus new PDCs with IntoCell and LegoChemBio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellectar Biosciences company profile →
Novosanis
HQ: Belgium
Website
- Description: Provider of medical devices enhancing accuracy of diagnostic tests and drug delivery, focused on prevention, detection and treatment of infectious diseases and oncology. Products include Colli-Pee, a urine collection device enabling volumetric, standardized first-void sampling to improve detection of infectious diseases and some cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novosanis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Credence MedSystems
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Credence MedSystems
2.2 - Growth funds investing in similar companies to Credence MedSystems
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Credence MedSystems
4.2 - Public trading comparable groups for Credence MedSystems
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →